Document:

EX-10.31

 Exhibit 10.31 
  

 FFG         

Project no. 846178/30000 SCK/SAI 
  

 Funding Contract 

executed between the 

Österreichische Forschungsförderungsgesellschaft mbH (FFG) 

as Funding Agency 
 and 

ARSANIS Biosciences GmbH 

Helmut-Qualtinger-Gasse 2 
 1030
Vienna 
 Company Register No. 354305m 

as Funding Recipient 
 § 1
Funding grant 
  

	1.1	On the basis of the funding application “Development of antibody-based therapeutics for the treatment of life-threatening pneumococcal diseases” received on 4/1/2014 via eCall, and based on the expert decision
of the Advisory Board in the meeting of 5/15/2014, funding is granted for the following project: 

 Project number: 846178
 
 eCall number: 4721069  

Pre-project number: 840293 

Project name (purpose of the agreement): 

Development of antibody-based therapeutics for the treatment of life- 

threatening pneumococcal diseases 

Program:           Base program 

  
 ./2 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna 
	  	 Phone +43 (0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 846178/30000 SCK/SAI 
  

 Page 2 

§ 2 Project period 
  

	2.1	The overall project period shall begin on 2/1/2013 and end on 5/31/2017. 

  

	2.2	Funding of the entire project by the FFG depends on the results as demonstrated in the submitted reports, the continued fulfillment of the evaluation and decision criteria, the budget available to the Funding Agency and
a new positive funding decision. 

 § 3 Funding period 

 

	3.1	The funding period of this project shall begin on the approval date 4/1/2014 and end on 3/31/2015. 

§ 4 Type and amount of funding 
  

	4.1	Funding will be awarded in the following form over the funding period specified in § 3: 

  

					
	 Type of funding
	  	Maximum amount	 
	 Subsidy granted by the FFG
	  	 	EUR 753,100.00	 
	 Loan granted by the FFG
	  	 	EUR 711,200.00	 

  

			
	Loan conditions	  	
	Interest rate	  	0.75% p.a. per current account
	Redemption date:	  	6/30/2022
	Redemption amount:	  	EUR 711,200.00
	Interest and loan collection:	  	automatic debit procedure
	Interest payment due:	  	semi-annually in arrears and/or upon maturity of the loan

  

	4.2	The funded financing of the project is 70.0% of the verifiable and eligible project costs. The Funding Recipient shall finance the remaining project costs. Based on the plan data, the cash value of the funding is EUR
794,436.00, i.e. 38.0% related to the eligible project costs pursuant to Point 5.1. 

  

	4.3	The maximum funding cash value according to the applicable Community Framework for public R&D subsidies is 45.0%. 

  

	4.4	A decrease in the eligible project costs shall entail a prorated cutback of the funding. 

  

	4.5	The eligible project costs pursuant to § 5 and the costs reported by way of interim and/or final accounts shall not be considered approved until a review by the FFG. The final amount of the approved overall project
costs as well as the funding shall be determined only after the completion of the project in the course of the final audit. 

  
 ./3 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 846178/30000 SCK/SAI 
  

 Page 3 

§ 5 Eligible costs 
  

	5.1	The funding is based on following eligible project costs: 

  

									
	 Personnel costs
	  	 	EUR	 	  	 	812,400.00	 
	 Cost of use of R&D infrastructure
	  	 	EUR	 	  	 	75,300.00	 
	 Cost of materials
	  	 	EUR	 	  	 	480,000.00	 
	 Third-party costs
	  	 	EUR	 	  	 	704,500.00	 
	 Travel costs
	  	 	EUR	 	  	 	19,800.00	 
	 Total eligible costs
	  	 	EUR	 	  	 	2,092,000.00	 

  

	5.2	All costs attributable to the project which are incurred directly, actually and additionally (to the normal operating expenses) during the funding period pursuant to § 3 are eligible costs. Additional supplementary
provisions regarding eligible costs may be found in the FFG Guidelines, the Guide for Individual Projects of Experimental Development and the “Guide for the Treatment of Project Costs in Funding Applications and Reports”.

  

	5.3	Major changes to the cost structure shall require the prior written approval of the FFG. 

  

	5.4	The turnover tax payable on the costs of eligible services is not an eligible cost. However, it is considered an eligible cost component if it can be demonstrated that said turnover tax must be borne in actual fact and
without recourse by the Funding Recipient, i.e. if it is not entitled to the input tax deduction. The refundable turnover tax—in whatever way—is not eligible even if it is not actually refunded to the Funding Recipient. If the tax office
considers funds which are taxable under the Turnover Tax Act 1994, Federal Gazette No. 663 not as funding but as a contractual compensation for services provided by the Funding Recipient to the Funding Agency, and if the Funding Recipient owes
turnover tax on such funds to the tax office, the contractual compensation shall be regarded as gross compensation. An additional, separate reimbursement of the turnover tax—for whatever legal reason—shall thus be excluded.

  

	5.5	If the amortization period of an asset (Sec. 285 ABGB [Allgemeines Bürgerliches Gesetzbuch (Civil Code)]) purchased for the implementation of the project exceeds the funding period, the depreciation costs
shall be eligible in the manner described in the Guide for Individual Projects of Experimental Development and the “Guide for the Treatment of Project Costs in Funding Applications and Reports”. 

 

	5.6	Funds provided by the Funding Agency may not be used for the creation of reserves or accruals under the Income Tax Act 1988, Federal Gazette No. 400. The funds may be used only for goods and services and for the
purposes described in the funding application. 

  

	5.7	In case of new applications, the eligible costs incurred after receipt of the funding application may be approved. In case of follow-up applications, the earliest date for cost approval shall be the beginning of the
funding period stated under § 3. 

  

	5.8	The costs of drawing up the agreement or the bank transfer expenses incurred by the Funding Recipient or its affiliates shall be borne by them and shall not be eligible costs. 

  
 ./4 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 846178/30000 SCK/SAI 
  

 Page 4 
  

	5.9	The Funding Agency reserves the right to postpone, cut back or suspend the disbursement of funding if and as long as circumstances prevail which might make it impossible to guarantee the proper execution of the promoted
project (e.g. if the documentary evidence for costs is not adequate). 

 § 6 Project-specific terms and conditions

  

	6.1	Project-specific special terms and conditions 

  

	 	1.	Acquisition costs for R&D infrastructure shall only be eligible if it was purchased during the funding period of the overall project. R&D infrastructure purchased outside of the funding period shall be billed at
the machine hour rate. Additional R&D infrastructure costs shall be billed as overhead costs via the personnel cost surcharge. The final determination and attribution will be made in the context of the FFG audit. 

 

	 	2.	The patent costs have been cut back overall. Only costs for first patent applications shall be funded. 

§ 7 Disbursement of the funds 
  

	7.1	The first installment in the amount of 50% of the promised funds will be disbursed after signature of the Funding Contract and fulfillment of the terms and conditions stipulated in § 6. 

The second installment in the amount of 30% will be disbursed after the approval of an interim report and an interim statement in which 50% of
the approved total costs must be documented, as well as after fulfillment of the terms and conditions stipulated in § 6. 
 The
final installment in the amount of 20% of the total promised funds will be disbursed only after fulfillment of all terms and conditions (final account, final reports, etc.) and after the audit and approval of the statement of use (discharge) by the
FFG. 
  

	7.2	The funds will be transferred to the following account of the Funding Recipient 

  

			
	Account holder:	  	ARSANIS Biosciences GmbH
	Name of the bank:	  	
	IBAN:	  	
	BIC/SWIFT:	  	

 § 8 Reporting obligations 

 

	8.1	According to Point 3 of the General Funding Terms and Conditions, the Funding Recipient must inform the FFG about the execution of the promoted project by submitting technical reports (interim and final reports) and
billing statements. The reports and billing statements must be submitted via eCall (https://ecall.ffg.at). The use of the forms to be found in eCall is mandatory. Other documents might have to be submitted at the request of the FFG.

 § 9 Amendments 
  

	9.1	Changes to this agreement may be made only explicitly and in writing. This shall apply also to any deviation from this requirement. 

  
 ./5 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 846178/30000 SCK/SAI 
  

 Page 5 
  

	9.2	Under special circumstances changes to the stipulated terms and conditions may, if necessary, be made later by mutual agreement in the form of written addenda if special circumstances are present and after a new
advisory board decision. 

 § 10 Legal liability 

 

	10.1	The Funding Recipient shall be unconditionally liable to the FFG for compliance with all contractual provisions. The Funding Recipient shall also be liable for the conduct of third parties for which it is responsible
(e.g. owners, corporate officers, etc.). The Funding Recipient must hold the FFG harmless against third parties. 

 §
11 Severability clause 
  

	11.1	In the event that be a provision of this Funding Contract is invalid, such event shall not affect the validity of the remaining provisions of the Funding Contract. The contractual partners undertake to replace an
invalid provision by such provision as comes closest to the purpose of this Funding Contract. 

 § 12 Applicable law

  

	12.1	This agreement and all its attachments shall be governed by Austrian law to the exclusion of the reference norms of the Austrian IPRG. 

§ 13 Legal venue 
  

	13.1	The legal venue agreed upon with regard to all legal disputes arising from the funding grant shall be the materially competent court in Vienna. The FFG reserves the right to take action against the Funding Recipient
also at the latter’s general legal venue. 

 § 14 Integral parts of the contract 

 

	14.1	The following documents are an integral part of the Funding Contract: 

  

	 	•	 	The funding application submitted via eCall (“Development of antibody-based therapeutics for the treatment of life-threatening pneumococcal diseases”) as amended on 4/1/2014 

 

	 	•	 	General terms and conditions for Funding Contracts as amended (version 1 of 2013) 

  

	 	•	 	Guide for Individual Projects of Experimental Development, version 1.0 

  

	 	•	 	Guide for the Treatment of Project Costs in Funding Applications and Reports for Projects with Funding Contracts according to the RTD Directives and the FFG Directives, version 1.4. 

 

	14.2	The legal bases of this Funding Contract are in particular: 

  

	 	•	 	Implementation Act of the Österreichische Forschungsförderungsgesellschaft mbH (Research Promotion Structural Reform Act), as amended 

 

	 	•	 	Guidelines of the Österreichische Forschungsförderungsgesellschaft mbH for promoting research, technology, development and innovation (FFG Guidelines GZ: BMVIT 609.986/0005-III/12/2008 and
BMWA-98.310/0032-C1/10/2008) 

  
 ./6 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 846178/30000 SCK/SAI 
  

 Page 6 
 The
Funding Recipient confirms being aware of all contract components and accepts them unconditionally. 
 It is pointed out that this funding offer is
considered revoked if the Funding Recipient does not sign it and return it to the FFG within 3 months. 
 For the Funding Agency: 

Österreichische Forschungsförderungsgesellschaft mbH (FFG) 

[stamp:] Austrian Research Promotion Agency               

 

							
	Vienna, on 5/20/2014	  		  		  	
				
	 /s/ Dr. Henrietta Egeth-Stadlhuber
	  		  	 /s/ Dr. Klaus Pseiner
	  	
	Dr. Henrietta Egerth-Stadlhuber	  		  	Dr. Klaus Pseiner	  	
	Director	  		  	Director	  	

 Funding Recipient 
  

							
	Vienna, on 6/9/2014	  		  	ARSANIS	  	
		  		  	Biosciences GmbH	  	
		  		  	MarxBox	  	
		  		  	Helmut-Qualtinger-Gasse 2	  	
		  		  	1030 Vienna	  	

  

					
	 /s/ Dr. Estzer Nagy
	 		 	
	Dr. Eszter Nagy, Director
	(company name, please indicate name and position in block letters, company seal)

 Attachments: 
 Guidelines for the
Österreichische Forschungsförderungsgesellschaft mbH for promoting research, technology, development and innovation (FFG Guidelines) per link https://www.ffg.at/Allgemeine-Richtlinien 

General terms and conditions for Funding Contracts as amended (version 1 of 2013) 

Guide for Individual Projects of Experimental Development, version 1.0 

Guide for the Treatment of Project Costs in Funding Applications and Reports for Projects with Funding Contracts according to the RTD Directives and the FFG
Directives, version 1.4. 

  
 ./7 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 846178/30000 SCK/SAI 
  

 ARSANIS Biosciences GmbH 

Attn.: Dr. Eszter Nagy 
 Helmut-Qualtinger-Gasse 2 

1030 Vienna 
 Account statement per 12/31/2014 

Project 846178 
 Development of antibody-based therapeutics for
the treatment of life-threatening pneumococcal diseases 
  

					
	 Account no.:
	  	 	18461780	 
	 Fiscal year:
	  	 	2014	 
	 Redemption amount (EUR):
	  	 	627,712.00	 
	 Date of redemption:
	  	 	6/30/2022	 
	 Interest rate:
	  	 	0.75	% 

  

					
		  	Balance per 12/31/2013 (EUR)	  	0.00
			
	Reference dates	  	Description of the transaction	  	Transacted amount (EUR)
			
	7/17/2014	  	846178 DA Installment 1 GP basis	  	-355,600.00
			
	12/1/2014	  	846178 Int. 0.75% per 12/31/14	  	-1,241.00
			
	12/31/2014	  	846178 Int. 0.75% per 12/31/14	  	1,241.00
			
		  	Debited amount (EUR)	  	356,841.00
			
		  	Deposited amount (EUR)	  	1,241.00
			
		  	Balance per 12/31/2014 (EUR)	  	-355,600.00

  
 ./8 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 846178/30000 SCK/SAI 
  

 ARSANIS Biosciences GmbH 

Attn.: Dr. Eszter Nagy 
 Helmut-Qualtinger-Gasse 2 

1030 Vienna 
 Account statement per 10/31/2015 

Project 846178 
 Development of antibody-based therapeutics for
the treatment of life-threatening pneumococcal diseases 
  

							
	 Account no.:
	  	 	18461780	 
	 Fiscal year:
	  	 	2015	 
	 Redemption amount (EUR):
	  	 	627,712.00	 
	 Date of redemption:
	  	 	6/30/2022	 
	 Interest rate:
	  	 	0.75	% 

  

					
		  	Balance per 12/31/2014 (EUR)	  	-355,600.00
			
	Reference dates	  	Description of the transaction	  	Transacted amount (EUR)
			
	1/29/2015	  	846178 DA Installment 2 GP basis	  	-213,360.00
			
	1/6/2015	  	846178 Int. 0.75% per 6/30/15	  	-2,021.00
			
	6/30/2015	  	846178 Int. 0.75% per 6/30/15	  	2,021.00
			
	07/23/2015	  	846178 DA Rate 3 BP-Basis	  	-58,752.00
			
		  	Debited amount (EUR)	  	274,133.00
			
		  	Deposited amount (EUR)	  	2,021.00
			
		  	Balance per 10/31/2015 (EUR)	  	-627,712.00

  
 ./9 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43(0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
ViennaEX-10.32

 Exhibit 10.32 
  

 FFG         

Project no. 851485/30000 SCK/SAI 
  

 Funding Contract 

executed between the 

Österreichische Forschungsförderungsgesellschaft mbH (FFG) 

as Funding Agency 
 and 

ARSANIS Biosciences GmbH 

Helmut-Qualtinger-Gasse 2 
 1030
Vienna 
 Company Register No. 354305m 

as Funding Recipient. 
 §
1 Funding grant 
  

	1.1	On the basis of the funding application “Development of antibody-based therapeutics for the treatment of life-threatening pneumococcal diseases” received on 5/7/2015 via eCall, and based on the expert decision
of the Advisory Board in the meeting of 7/1/2015, funding is granted for the following project: 

 Project number: 851485
 
 eCall number: 5795972  

Pre-project number: 846178 

Project name (purpose of the agreement): 

Development of antibody-based therapeutics for the treatment of life-threatening pneumococcal diseases 

Program:   Base program 

  
 ./2 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43 (0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 851485/30000 SCK/SAI 
  Page
 2
 
  

 § 2 Project period 

 

	2.1	The overall project period shall begin on 2/1/2013 and end on 5/31/2017. 

  

	2.2	Funding of the entire project by the FFG depends on the results as demonstrated in the submitted reports, the continued fulfillment of the evaluation and decision criteria, the budget available to the Funding Agency and
a new positive funding decision. 

 § 3 Funding period 

 

	3.1	The funding period of this project shall begin on the approval date 5/1/2015 and end on 4/30/2016. 

§ 4 Type and amount of funding 
  

	4.1	Funding will be awarded in the following form over the funding period specified in § 3: 

  

					
	 Type of funding
	  	Maximum amount	 
	 Subsidy granted by the FFG
	  	EUR	 708,200.00	 
	 Loan granted by the FFG
	  	EUR	 794,000.00	 

 Loan conditions 
  

			
	Interest rate	  	0.75% p.a. per current account
		
	Redemption date:	  	6/30/2022
		
	Redemption amount:	  	EUR 794,000.00
		
	Interest and loan collection:	  	automatic debit procedure
		
	Interest payment due:	  	semi-annually in arrears and/or upon maturity of the loan

  

	4.2	The funded financing of the project is 70.0% of the verifiable and eligible project costs. The Funding Recipient shall finance the remaining project costs. Based on the plan data, the cash value of the funding is EUR
833,687.00, i.e. 38.8% related to the eligible project costs pursuant to Point 5.1. 

  

	4.3	The maximum funding cash value according to the applicable Community Framework for public subsidies funding research, development and innovation is 45.0%. 

 

	4.4	A decrease in the eligible project costs shall entail a prorated cutback of the funding. 

  

	4.5	The eligible project costs pursuant to § 5 and the costs reported by way of interim and/or final accounts shall not be considered approved until a review by the FFG. The final amount of the approved overall project
costs as well as the funding shall be determined only after the completion of the project in the course of the final audit. 

  
 ./3 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43 (0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 851485/30000 SCK/SAI 
  Page
 3
 
  

 § 5 Eligible costs 

 

	5.1	The funding is based on following eligible project costs: 

  

									
	 Personnel costs
	  	 	EUR	 	  	 	804,500.00	 
	 Cost of materials
	  	 	EUR	 	  	 	656,200.00	 
	 Third-party costs
	  	 	EUR	 	  	 	660,700.00	 
	 Travel costs
	  	 	EUR	 	  	 	24,800.00	 
	 Total eligible costs
	  	 	EUR	 	  	 	2,146,200.00	 

  

	5.2	All costs attributable to the project which are incurred directly, actually and additionally (to the normal operating expenses) during the funding period pursuant to § 3 are eligible costs. Additional supplementary
provisions regarding eligible costs may be found in the FFG Guidelines “KMU”, the Cost Guidelines and Guide for Individual Projects of Experimental Development (in each case in the version mentioned under 14.1). 

 

	5.3	Major changes to the cost structure shall require the prior written approval of the FFG. 

  

	5.4	The turnover tax payable on the costs of eligible goods and services is not an eligible cost. However, it is considered an eligible cost component if said turnover tax must be borne verifiably in actual fact and without
recourse by the Funding Recipient, i.e. if it is not entitled to the input tax deduction. 

 Any funds granted by the Funding
Agency is a genuine subsidy not subject to the turnover tax because no exchange of services takes place and there is a public interest in the execution of the research project. 

The funding amount is a gross amount. Any additional, separate refund of fees and taxes by the FFG – for whatever legal reason –
shall be excluded. 
 The interest on the loan/the fee for assuming a liability is exempted from the turnover tax pursuant to § 6 para.
1 line 8 UStG [Umsatzsteuergesetz (Turnover Tax Act)]. 
  

	5.5	If the amortization period of an asset (Sec. 285 ABGB [Allgemeines Bürgerliches Gesetzbuch (Civil Code)]) purchased for the implementation of the project exceeds the funding period, the depreciation costs
shall be eligible in the manner described in the Guide for Individual Projects of Experimental Development and the Cost Guidelines (in each case in the version mentioned under 14.1). 

 

	5.6	Funds provided by the Funding Agency may not be used for the creation of reserves or accruals under the Income Tax Act 1988, Federal Gazette No. 400/1988. The funds may be used only for goods and services and for
the purposes described in the funding application. 

  

	5.7	The costs of drawing up the agreement or the bank transfer expenses incurred by the Funding Recipient or its affiliates shall be borne by them and shall not be eligible costs. 

 

	5.8	The Funding Agency reserves the right to postpone, cut back or suspend the disbursement of funding if and as long as circumstances prevail which might make it impossible to guarantee the proper execution of the promoted
project (e.g. if the documentary evidence for costs is not adequate). 

  
 ./3 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43 (0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 851485/30000 SCK/SAI 
  Page
 4
 
  

	5.9	The funds made available by the FFG for paying the costs and expenses directly incurred in the promotion of science and research are taken from public funds and are tax-free pursuant to Sec. 3 para. 1 line 3 lit c) EStG
[Einkommensteuergesetz (Income Tax Act)] in conj. with Sec. 3 para. 4 line 3 EStG. 

 § 6 Terms and conditions

  

	6.1	Project-specific special terms and conditions 

  

	 	1.	The costs of Mrs. Nagy were reduced to 400h. 

  

	 	2.	A complete resources summary of the involved project workers for all current FFG projects must be submitted in the course of the project close-out. 

 

	 	3.	The funding shall be tied to the continued existence of the development location including the personal and the IP rights until at least 5/31/2020. 

 

	6.2	The original signed Funding Contract must be returned to the Funding Agency at the latest 4 weeks after receipt. 

  

	6.3	With the signing of this Funding Contract the Funding Recipient undertakes to inform the Funding Agency all applied for and/or approved public grants directly or indirectly concerning the project at the latest in the
course of the planned reports. 

 § 7 Disbursement of the funds 

 

	7.1	The first installment in the amount of 50% of the promised funds will be disbursed after signature of the Funding Contract and fulfillment of the terms and conditions stipulated in § 6. 

The second installment in the amount of 30% will be disbursed after the approval of an interim report in which 50% of the approved total costs
must be documented, as well as after fulfillment of the terms and conditions stipulated in § 6. 
 The final installment in the amount
of 20% of the total promised funds will be disbursed only after fulfillment of all terms and conditions (final account, final reports, etc.) and after the audit and approval of the statement of use (discharge) by the FFG. 

 

	7.2	The funds will be transferred to the following account of the Funding Recipient 

  

			
	Account holder:	  	ARSANIS Biosciences GmbH
		
	Name of the bank:	  	
		
	IBAN:	  	
		
	BIC/SWIFT:	  	

 § 8 Reporting obligations 

 

	8.1	According to Point 3 of the General Funding Terms and Conditions, the Funding Recipient must inform the FFG about the execution of the promoted project by submitting technical reports (interim and final reports) and
billing statements. The reports and billing statements must be submitted via eCall (https://ecall.ffg.at). The use of the forms to be found in eCall is mandatory. Other documents might have to be submitted at the request of the FFG.

  
 ./4 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43 (0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 851485/30000 SCK/SAI 
  Page
 5
 
  

	8.2	In case of the promotion of prototypes, the Funding Recipient must inform the FFG about the whereabouts and/or the further use of the prototypes. 

§ 9 Amendments 
  

	9.1	Changes to this agreement may be made only explicitly and in writing. This shall apply also to any deviation from this requirement. 

  

	9.2	Under special circumstances changes to the stipulated terms and conditions may, if necessary, be made later by mutual agreement in the form of written addenda if special circumstances are present and after a new
advisory board decision. 

 § 10 Legal liability 

 

	10.1	The Funding Recipient shall be unconditionally liable to the FFG for compliance with all contractual provisions. The Funding Recipient shall also be liable for the conduct of third parties for which it is responsible
(e.g. owners, corporate officers, etc.). The Funding Recipient must hold the FFG harmless against third parties. 

 §
11 Severability clause 
  

	11.1	In the event that be a provision of this Funding Contract is invalid, such event shall not affect the validity of the remaining provisions of the Funding Contract. The contractual partners undertake to replace an
invalid provision by such provision as comes closest to the purpose of this Funding Contract. 

 § 12 Applicable law

  

	12.1	This agreement and all its attachments shall be governed by Austrian law to the exclusion of the reference norms of the Austrian IPRG. 

§ 13 Legal venue 
  

	13.1	The legal venue agreed upon with regard to all legal disputes arising from the funding grant shall be the materially competent court in Vienna. The FFG reserves the right to take action against the Funding Recipient
also at the latter’s general legal venue. 

 § 14 Integral parts of the contract 

 

	14.1	The following documents are an integral part of the Funding Contract: 

  

	 	•	 	The funding application submitted via eCall (“Development of antibody-based therapeutics for the treatment of life-threatening pneumococcal diseases”) as amended on 5/7/2015 

 

	 	•	 	General terms and conditions for Funding Contracts as amended (version 2015) 

  

	 	•	 	Guide for Individual Projects of Experimental Development, version 3.0 

  

	 	•	 	Guide Guidelines, version 2.0 

  
 ./5 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43 (0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 851485/30000 SCK/SAI 
  Page
 6
 
  

	14.2	The legal bases of this Funding Contract are in particular: 

  

	 	•	 	Implementation Act of the Österreichische Forschungsförderungsgesellschaft mbH (Research Promotion Structural Reform Act), as amended 

 

	 	•	 	Community Framework for Public Subsidies Promoting Research, Development and Innovation (Federal Gazette C 198 of 6/27/2014) 

  

	 	•	 	Regulation (EU) Nr.651/2014 of the Commission of June 17, 2014 for determining the compatibility of certain groups of subsidies with the domestic market in application of Articles 107 and 108 of the Treaty
regarding the functioning of the European Union (TFEU 2014) 

  

	 	•	 	Guidelines for the Österreichische Forschungsförderungsgesellschaft mbH for the promotion of applied research, development and innovation (FFG Guidelines “KMU” GZ: BMVIT 609.986/0012-III/12/2014 and
BMWFW-98. 310/0102-C1/10/2014)—These Guidelines were filed for exemption with the European Commission on the basis of the TFEU 2014. 

  
 ./6 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43 (0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 851485/30000 SCK/SAI 
  Page
 7
 
  

 The Funding Recipient confirms being aware of all contract components and accepts them unconditionally,
taking also note of the fact that non-compliance with the specified contractual provisions may lead to the granted funds being reclaimed. 
 Die Funding
Recipient confirms that no open reclaim order by the European Commission exists and that rescission, if any, of an incompatible funding is completed. 
 The
Funding Recipient agrees that the data enumerated pursuant to Art. 9 para. 1 TFEU (Regulation EU No. 651/2014) Annex III will be used for publishing information if the cash value of the funding exceeds € 500,000.00 (gross subsidy
equivalent). 
 For the Funding Agency: 

Österreichische Forschungsförderungsgesellschaft mbH (FFG) 

[stamp:] Austrian Research Promotion Agency                 

Vienna, on 7/8//2015 
  

					
	 /s/ Dr. Henrietta Egeth-Stadlhuber
	 		 	 /s/ Dr. Klaus Pseiner

	Dr. Henrietta Egerth-Stadlhuber	 		 	Dr. Klaus Pseiner
	Director	 		 	Director

 Funding Recipient 
  

			
	Vienna, on 7/20/2015	  	              ARSANIS
		  	              Biosciences GmbH
		  	              MarxBox
		  	              Helmut-Qualtinger-Gasse 2
		  	              1030 Vienna

 /s/ Dr. Estzer
Nagy                     
 (company name, please
indicate name and position in block letters, company seal) 
 Dr. Eszter Nagy, Director 

Attachments: 
 Guidelines for the Österreichische
Forschungsförderungsgesellschaft mbH for promoting applied research, development and innovation (FFG Guidelines “KMU”) 
 per link
https://www.ffg.at/recht-finanzen/rechtsgrundlagen 
 General terms and conditions for Funding Contracts as amended (version 2015) 

Guide for Individual Projects of Experimental Development, version 3.0 

Cost Guidelines, version 2.0 

  
 ./7 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43 (0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna
	  	

 FFG         

Project no. 851485/30000 SCK/SAI 
  

 ARSANIS Biosciences GmbH 

Attn.: Dr. Eszter Nagy 
 Helmut-Qualtinger-Gasse 2 

1030 Vienna 
 Account statement per 10/31/2015 

Project 851485 
 Development of antibody-based therapeutics for
the treatment of life-threatening pneumococcal diseases 
  

					
	 Account no.:
	  	 	18514850	 
	 Fiscal year:
	  	 	2015	 
	 Redemption amount (EUR):
	  	 	397,000.00	 
	 Date of redemption:
	  	 	6/30/2022	 
	 Interest rate:
	  	 	0.75	% 

  

					
		 	Balance per 12/31/2014 (EUR)	  	0.00
			
	Reference dates	 	Description of the transaction	  	Transacted amount (EUR)
			
	7/23/2015	 	851485 DA Installment 1 GP basis	  	-397,000.00
			
		 	Debited amount (EUR)	  	397,000.00
			
		 	Deposited amount (EUR)	  	0.00
			
		 	Balance per 10/31/2015 (EUR)	  	-397,000.00

  
 ./8 

 

					
	 Österreichische

Forschungsförderungsgesellschaft mbH
 Sensengasse

1090 Vienna
	  	 Phone +43 (0)5 7755 - 0
 Fax+43 (0) 5 7755
-97900
 www.ffg.at, office@ffg.at
 FN 252263a Comm. Court
Vienna

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]